ReviewFrontiers in oncology2022
Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects.Frontiers in immunology · 2024Pooled it
- Article
- Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1.Discover oncology · 2026Review
- Survival benefits of immunotherapy combined with chemoradiotherapy in metastatic colorectal cancer: an analysis based on data from the SEER database.Open medicine (Warsaw, Poland) · 2026Article
- From local control to immune modulation: hypofractionated radiotherapy as a backbone for cancer immunotherapy.Frontiers in oncology · 2026Review
- Synergizing radiotherapy and immunotherapy for locally advanced gastric cancer: evolving paradigms and future directions.Frontiers in immunology · 2026Review
- Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer.Annals of medicine · 2025Review
- PARP7 Suppresses Radiation-induced Necroptosis and Abscopal Immunity.Research square · 2025Article
- Identification and validation of cuproptosis-related immune checkpoint expression for glioblastoma.BMC cancer · 2025Article
- The silent protectors: how neutrophils influence female fertility during cancer treatment - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Improved Tumor Blood Flow Enhances the Abscopal Effect: Preclinical Assessment in Mice Treated with Combined Radiation and PD-1 Blockade Therapy.bioRxiv : the preprint server for biology · 2025Article
- Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors.Frontiers in immunology · 2025Review
- Immunotherapy in cervical cancer: an innovative approach for better treatment outcomes.Exploration of targeted anti-tumor therapy · 2025Review
- Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches.Frontiers in immunology · 2025Review
- Dual Targeting of Inflammatory and Immune Checkpoint Pathways to Overcome Radiotherapy Resistance in Esophageal Squamous Cell Carcinoma.Journal of inflammation research · 2025Review
- Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy.Biomarker research · 2024Review
- Article
- Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.The clinical respiratory journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immuno-oncology is an emerging field in the treatment of oncological diseases, that is based on recruitment of the host immune system to attack the tumor. Radiation exposure may help to unlock the potential of the immune activating agents by enhancing the antigen release and presentation, attraction of immunocompetent cells to the inflammation site, and eliminating the tumor cells by phagocytosis, thereby leading to an overall enhancement of the immune response. Numerous preclinical studies in mouse models of glioma, murine melanoma, extracranial cancer, or colorectal cancer have contributed to determination of the optimal radiotherapy fractionation, as well as the radio- and immunotherapy sequencing strategies for maximizing the antitumor activity of the treatment regimen. At the same time, efficacy of combined radio- and immunotherapy has been actively investigated in clinical trials of metastatic melanoma, non-small-cell lung cancer and renal cell carcinoma. The present review summarizes the current advancements and challenges related to the aforementioned treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.